EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

News
Video

Terence Friedlander, MD, presents significant data from the EV-302/KEYNOTE-A39 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Related Videos
Joaquim Bellmunt, MD, PhD
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Vikram Narayan, MD
Scott T. Tagawa, MD, MS, FACP, FASCO
Jason Efstathiou, MD, DPhil
Daniel Petrylak, MD
Bernard H. Bochner, MD, FACS
Nikhil A. Gopal, MD
Related Content
Mark D. Tyson, II, MD, MPH

Cretostimogene Monotherapy Elicits Durable CRs in High-Risk NMIBC

May 3rd 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Karim Chamie, MD

N-803/BCG Approval Signals Paradigm Shift in Management of BCG-Unresponsive NMIBC

May 1st 2024
Article
Terence Friedlander, MD

FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

April 24th 2023
Podcast
FDA

FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for BCG-Unresponsive NMIBC

April 22nd 2024
Article
Vikram Narayan, MD

Narayan Details How Nadofaragene Firadenovec Has Broken Ground as the First Gene Therapy for NMIBC

April 18th 2024
Article